GimotiTM is interesting new product development by Evoke Pharma. GimotiTM is a metoclopramide nasal spray developed for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis.
Currently, only oral and intravenous metoclopramide products are approved for Gastroparesis. Oral absorption may be unpredictable in patient with Gastroparesis. Non-oral form available is only injection wherein patient compliance may not be good.
As per company website “Evoke pharma believes that GimotiTM may be tolerated even when patients are experiencing nausea and vomiting.”
Recently on Aug 16, 2018, USFDA accepted NDA application for review. Target PDUFA date for this product is Apr 1, 2019.
For more details, please visit Evoke Pharmaceuticals Website.
